Oct. 29, 2015—Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.
Oct. 25, 2012—Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene.
Jul. 26, 2012—An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to a specific drug therapy, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.
Mar. 23, 2012—A new study offers clues on why melanoma patients who are treated with oral drugs inhibiting the BRAF gene are at increased risk for developing secondary skin cancers.
Feb. 23, 2012—Investigators from Vanderbilt-Ingram Cancer Center and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.